These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

829 related articles for article (PubMed ID: 33572467)

  • 1. Brilacidin Demonstrates Inhibition of SARS-CoV-2 in Cell Culture.
    Bakovic A; Risner K; Bhalla N; Alem F; Chang TL; Weston WK; Harness JA; Narayanan A
    Viruses; 2021 Feb; 13(2):. PubMed ID: 33572467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The folate antagonist methotrexate diminishes replication of the coronavirus SARS-CoV-2 and enhances the antiviral efficacy of remdesivir in cell culture models.
    Stegmann KM; Dickmanns A; Gerber S; Nikolova V; Klemke L; Manzini V; Schlösser D; Bierwirth C; Freund J; Sitte M; Lugert R; Salinas G; Meister TL; Pfaender S; Görlich D; Wollnik B; Groß U; Dobbelstein M
    Virus Res; 2021 Sep; 302():198469. PubMed ID: 34090962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stenoparib, an Inhibitor of Cellular Poly(ADP-Ribose) Polymerase, Blocks Replication of the SARS-CoV-2 and HCoV-NL63 Human Coronaviruses
    Stone NE; Jaramillo SA; Jones AN; Vazquez AJ; Martz M; Versluis LM; Raniere MO; Nunnally HE; Zarn KE; Nottingham R; Ng KR; Sahl JW; Wagner DM; Knudsen S; Settles EW; Keim P; French CT
    mBio; 2021 Jan; 12(1):. PubMed ID: 33468703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Antiviral Activity of Gemcitabine with 2'-Fluoro-2'-Deoxycytidine and Combination Therapy with Remdesivir against SARS-CoV-2.
    Jang Y; Shin JS; Lee MK; Jung E; An T; Kim UI; Kim K; Kim M
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33557278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brilacidin, a COVID-19 drug candidate, demonstrates broad-spectrum antiviral activity against human coronaviruses OC43, 229E, and NL63 through targeting both the virus and the host cell.
    Hu Y; Jo H; DeGrado WF; Wang J
    J Med Virol; 2022 May; 94(5):2188-2200. PubMed ID: 35080027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery and Evaluation of Entry Inhibitors for SARS-CoV-2 and Its Emerging Variants.
    Acharya A; Pandey K; Thurman M; Klug E; Trivedi J; Sharma K; Lorson CL; Singh K; Byrareddy SN
    J Virol; 2021 Nov; 95(24):e0143721. PubMed ID: 34550770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic Block of SARS-CoV-2 Infection by Combined Drug Inhibition of the Host Entry Factors PIKfyve Kinase and TMPRSS2 Protease.
    Kreutzberger AJB; Sanyal A; Ojha R; Pyle JD; Vapalahti O; Balistreri G; Kirchhausen T
    J Virol; 2021 Oct; 95(21):e0097521. PubMed ID: 34406858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human soluble ACE2 improves the effect of remdesivir in SARS-CoV-2 infection.
    Monteil V; Dyczynski M; Lauschke VM; Kwon H; Wirnsberger G; Youhanna S; Zhang H; Slutsky AS; Hurtado Del Pozo C; Horn M; Montserrat N; Penninger JM; Mirazimi A
    EMBO Mol Med; 2021 Jan; 13(1):e13426. PubMed ID: 33179852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of itraconazole against SARS-CoV-2.
    Van Damme E; De Meyer S; Bojkova D; Ciesek S; Cinatl J; De Jonghe S; Jochmans D; Leyssen P; Buyck C; Neyts J; Van Loock M
    J Med Virol; 2021 Jul; 93(7):4454-4460. PubMed ID: 33666253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacologic profiling reveals lapatinib as a novel antiviral against SARS-CoV-2 in vitro.
    Raymonda MH; Ciesla JH; Monaghan M; Leach J; Asantewaa G; Smorodintsev-Schiller LA; Lutz MM; Schafer XL; Takimoto T; Dewhurst S; Munger J; Harris IS
    Virology; 2022 Jan; 566():60-68. PubMed ID: 34871905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparative analysis of remdesivir and other repurposed antivirals against SARS-CoV-2.
    Simonis A; Theobald SJ; Fätkenheuer G; Rybniker J; Malin JJ
    EMBO Mol Med; 2021 Jan; 13(1):e13105. PubMed ID: 33015938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of coronavirus infection by a synthetic STING agonist in primary human airway system.
    Zhu Q; Zhang Y; Wang L; Yao X; Wu D; Cheng J; Pan X; Liu H; Yan Z; Gao L
    Antiviral Res; 2021 Mar; 187():105015. PubMed ID: 33444702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiviral activity and safety of remdesivir against SARS-CoV-2 infection in human pluripotent stem cell-derived cardiomyocytes.
    Choi SW; Shin JS; Park SJ; Jung E; Park YG; Lee J; Kim SJ; Park HJ; Lee JH; Park SM; Moon SH; Ban K; Go YY
    Antiviral Res; 2020 Dec; 184():104955. PubMed ID: 33091434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis C virus drugs that inhibit SARS-CoV-2 papain-like protease synergize with remdesivir to suppress viral replication in cell culture.
    Bafna K; White K; Harish B; Rosales R; Ramelot TA; Acton TB; Moreno E; Kehrer T; Miorin L; Royer CA; García-Sastre A; Krug RM; Montelione GT
    Cell Rep; 2021 May; 35(7):109133. PubMed ID: 33984267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IMU-838, a Developmental DHODH Inhibitor in Phase II for Autoimmune Disease, Shows Anti-SARS-CoV-2 and Broad-Spectrum Antiviral Efficacy In Vitro.
    Hahn F; Wangen C; Häge S; Peter AS; Dobler G; Hurst B; Julander J; Fuchs J; Ruzsics Z; Überla K; Jäck HM; Ptak R; Muehler A; Gröppel M; Vitt D; Peelen E; Kohlhof H; Marschall M
    Viruses; 2020 Dec; 12(12):. PubMed ID: 33291455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Boceprevir, Calpain Inhibitors II and XII, and GC-376 Have Broad-Spectrum Antiviral Activity against Coronaviruses.
    Hu Y; Ma C; Szeto T; Hurst B; Tarbet B; Wang J
    ACS Infect Dis; 2021 Mar; 7(3):586-597. PubMed ID: 33645977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting host inducible-heat shock protein 70 with PES-Cl is a promising antiviral strategy against SARS-CoV-2 infection and pathogenesis.
    Joshi P; Garg S; Mani S; Shoaib R; Jakhar K; Almuqdadi HTA; Sonar S; Marothia M; Behl A; Biswas S; Singhal J; Kahlon AK; Shevtsov M; Abid M; Garg P; Ranganathan A; Singh S
    Int J Biol Macromol; 2024 Nov; 279(Pt 1):135069. PubMed ID: 39187102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A.
    White KM; Rosales R; Yildiz S; Kehrer T; Miorin L; Moreno E; Jangra S; Uccellini MB; Rathnasinghe R; Coughlan L; Martinez-Romero C; Batra J; Rojc A; Bouhaddou M; Fabius JM; Obernier K; Dejosez M; Guillén MJ; Losada A; Avilés P; Schotsaert M; Zwaka T; Vignuzzi M; Shokat KM; Krogan NJ; García-Sastre A
    Science; 2021 Feb; 371(6532):926-931. PubMed ID: 33495306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of SARS-CoV-2 polymerase by nucleotide analogs from a single-molecule perspective.
    Seifert M; Bera SC; van Nies P; Kirchdoerfer RN; Shannon A; Le TT; Meng X; Xia H; Wood JM; Harris LD; Papini FS; Arnold JJ; Almo S; Grove TL; Shi PY; Xiang Y; Canard B; Depken M; Cameron CE; Dulin D
    Elife; 2021 Oct; 10():. PubMed ID: 34617885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. On the molecular structure of Remdesivir for the treatment of Covid-19.
    Sheikholeslami SM; Jahanbani A; Shao Z
    Comput Methods Biomech Biomed Engin; 2021 Jul; 24(9):995-1002. PubMed ID: 33356621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.